Cargando…
Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
Atrial fibrillation is the most frequent arrhythmia in clinical practice, reaching 2% of the people in the world and is associated with systemic embolism. Thus, the use of anticoagulants is indicated if CHA2DS2-VASc score ≥2 or in patients with previous transient ischemic attack or stroke. For decad...
Autor principal: | da Silva, Rose M.F.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428103/ https://www.ncbi.nlm.nih.gov/pubmed/25470147 http://dx.doi.org/10.2174/187152571201141201091848 |
Ejemplares similares
-
Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
por: Halperin, Jonathan L, et al.
Publicado: (2014) -
Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012) -
Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021) -
Psychological effects of treatment with novel oral anticoagulants in non-valvular atrial fibrillation patients
por: Öncel, Can Ramazan
Publicado: (2016) -
Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)